# US 2024/0002905 A1 · Pathogen inactivating and nucleic acid stabilization media for microorganism collection and transport

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0002905 A1
- Document ID: US20240002905A1
- Status: Published application
- Kind: A1
- Application number: 18/252,684
- Filed: 2021-11-11
- Published: 2024-01-04
- Earliest claimed: 2020-11-11
- Assignees: Biocept, Inc.
- Applicants: Biocept, Inc.
- Inventors: Lyle ARNOLD
- Web page: https://patentgrep.com/patent/US20240002905A1

## CPC

- C12Q 1/18: Testing for antimicrobial activity of a material
- C12Q 1/6806: Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay (C12Q1/6804 takes precedence)
- C12Q 1/02: involving viable microorganisms
- C12Q 1/701: {Specific hybridization probes}
- C12Q: MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS (immunoassay G01N33/53); COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES

## Abstract

The present disclosure provides pathogen inactivating formulations, and methods of use thereof in collecting, transporting and storing biological samples, as well as preventing degradation of and purifying nucleic acids. The disclosure further provides methods of preparing compositions comprising the pathogen inactivating formulation and a biological sample.

## Claims

### Claim 1

A formulation for lysing cells in a biological sample and stabilizing the RNA contained in said cells, comprising a detergent, a metal chelating agent and a buffer, wherein the concentration of the detergent is in the range of about 0.1% to about 3%, wherein the concentration of the metal chelating agent is in the range of about 0.1 mM to about 5.0 mM, wherein the concentration of the buffer is in the range of about 20 mM to about 40 mM and wherein contact of the formulation with a biological sample results in one or more of the following: (a) inactivation of a nuclease in the biological sample, (b) inactivation of a pathogenic microbe in the biological sample, (c) disruption of an association of a protein with a nucleic acid in the biological sample, and (d) reduction or prevention of degradation of a nucleic acid in the biological sample, wherein the biological sample is derived from a subject.

### Claim at position 2

2-6. (canceled)

### Claim 7 (depends on 1)

The formulation according to claim 1, wherein the detergent is selected from the group consisting of sodium lauryl sulfate, sodium lauryl sarcosine, sodium octyl sulfate, sodium dihexadecyl phosphate, sodium taurodeoxycholate, sodium taurocholate, sodium glycocholate, sodium deoxycholate, sodium cholate, and sodium alkylbenzene sulfonate.

### Claim 8

(canceled)

### Claim 9 (depends on 1)

The formulation according to claim 1, wherein the metal chelating agent is selected from the group consisting of ethylene glycol tetraacetic acid (EGTA), hydroxyl ethylethylenediaminetriacetic acid, diethylene triamine penta acetic acid, N,N-bis(carboxymethyl)glycine, ethylene diamine tetraacetic acid (EDTA), citrate anhydrous, sodium citrate, calcium citrate, ammonium citrate, ammonium bicitrate, citric acid, diammonium citrate, ferric ammonium citrate, and lithium citrate.

### Claim at position 6

10-11. (canceled)

### Claim 12 (depends on 1)

The formulation according to claim 1, wherein the buffer comprises tris(hydroxymethyl)aminomethane, citrate, 2-(N-morpholino)ethanesulfonic acid, N,N-Bis(2-hydroxyethyl)-2-aminoethanesulfonic acid, 1,3-bis(tris(hydroxymethyl)methyl amino)propane, 4-(2-hydroxy ethyl)-1-piperazine ethanesulfonic acid, 3-(N-morpholino) propanesulfonic acid, bicarbonate, or phosphate.

### Claim at position 8

13-14. (canceled)

### Claim 15 (depends on 1)

The formulation according to claim 1, wherein the formulation has a pH in the range of about 6.5 to about 7.5.

### Claim at position 10

16-23. (canceled)

### Claim 24 (depends on 1)

The formulation according to claim 1, wherein the biological sample comprises a nasal sample, an oral sample, a saliva sample, a urine sample, a stool sample, a bronchoalveolar lavage sample, a nasopharyngeal aspirate sampled cerebrospinal fluid sample, a pleural effusion sample, a peritoneal effusion sample, or a blood sample.

### Claim at position 12

25-27. (canceled)

### Claim 28 (depends on 1)

The formulation according to claim 1, wherein the nuclease in the biological sample is an RNase.

### Claim at position 14

29-34. (canceled)

### Claim 35 (depends on 1)

The formulation according to claim 1, wherein the pathogenic microbe is a bacterium, fungus, virus, or parasite.

### Claim 36

(canceled)

### Claim 37 (depends on 35)

The formulation according to claim 35, wherein the virus is selected from the group consisting of SARS-CoV-2, SARS-CoV-1, MERS-CoV, chikungunya virus, African Swine Fever virus, Dengue virus, Zika virus, Influenza virus A, Influenza virus B, Influenza virus C, Human Immunodeficiency Virus (HIV), Ebola virus, Hepatitis virus A, Hepatitis virus B, Hepatitis virus C, Hepatitis virus D, and Hepatitis virus E, herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2) and Human Papillomavirus.

### Claim at position 18

38-41. (canceled)

### Claim 42 (depends on 1)

The formulation according to claim 1, wherein degradation of the nucleic acid is reduced or prevented for at least about 1 day, at least about 1 day at room temperature, at least 3 days at room temperature or at least about 1 month at room temperature.

### Claim at position 20

43-45. (canceled)

### Claim 46 (depends on 42)

The formulation according to claim 42, wherein the nucleic acid is derived from a pathogenic microbe.

### Claim 47 (depends on 42)

The formulation according to claim 42, wherein the nucleic acid is an RNA, a DNA, or a combination thereof.

### Claim at position 23

48-49. (canceled)

### Claim 50

A formulation, comprising: (a) about 3% sodium lauryl sulfate; (b) about 1 mM each of the EDTA and EGTA; and (c) about 30 mM of phosphate buffer; wherein the formulation has a pH of about 6.7, and wherein the formulation does not comprise guanidinium thiocyanate.

### Claim 51

(canceled)

### Claim 52 (depends on 1)

A sample collection system, comprising: a collection device or a collection vessel; and the formulation according to claim 1.

### Claim at position 27

53-63. (canceled)

### Claim 64 (depends on 1)

A method of purifying a nucleic acid from a biological sample, comprising (a) collecting the biological sample from a subject, (b) bringing the biological sample in contact with the formulation according to claim 1 to form a composition, and (c) purifying the nucleic acid from the composition.

### Claim at position 29

65-73. (canceled)

### Claim 74 (depends on 64)

The method according to claim 64, wherein the method comprises transporting and/or storing the composition at room temperature for at least about 1 day, for at least about 1 day at room temperature, at least about three days at room temperature or at least about a month at room temperature.

### Claim at position 31

75-80. (canceled)
